Inmune Bio Inc Financials

INMB

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Inmune Bio Inc (INMB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 48/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Inmune Bio Inc has an operating margin of -304535.7%, meaning the company retains $-304536 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -19187.7% the prior year.

Growth

Inmune Bio Inc's revenue declined 91% year-over-year, from $155K to $14K. This contraction results in a growth score of 0/100.

Leverage

Inmune Bio Inc carries a low D/E ratio of 0.47, meaning only $0.47 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 3.14, Inmune Bio Inc holds $3.14 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Piotroski F-Score Weak

2/9

Inmune Bio Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.79x

For every $1 of reported earnings, Inmune Bio Inc generates $0.79 in operating cash flow (-$33.4M OCF vs -$42.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-119.4x

Inmune Bio Inc earns $-119.4 in operating income for every $1 of interest expense (-$42.6M vs $357K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

$14K

YoY-91.0%

Inmune Bio Inc generated $14K in revenue in fiscal year 2024. This represents a decrease of 91.0% from the prior year.

EBITDA

N/A

Free Cash Flow

N/A

Net Income

-$42.1M

YoY-40.2%

Inmune Bio Inc reported -$42.1M in net income in fiscal year 2024. This represents a decrease of 40.2% from the prior year.

EPS (Diluted)

$-2.11

YoY-26.3%

Inmune Bio Inc earned $-2.11 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 26.3% from the prior year.

Cash & Debt

$20.9M

YoY-41.6%

5Y CAGR+24.5%

Inmune Bio Inc held $20.9M in cash against $15.0M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

22M

YoY+24.1%

5Y CAGR+15.6%

Inmune Bio Inc had 22M shares outstanding in fiscal year 2024. This represents an increase of 24.1% from the prior year.

Gross Margin

N/A

Operating Margin

-304535.7%

YoY-285348.0pp

Inmune Bio Inc's operating margin was -304535.7% in fiscal year 2024, reflecting core business profitability. This is down 285348.0 percentage points from the prior year.

Net Margin

-300585.7%

YoY-281225.7pp

Inmune Bio Inc's net profit margin was -300585.7% in fiscal year 2024, showing the share of revenue converted to profit. This is down 281225.7 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$33.2M

YoY+63.6%

5Y CAGR+58.8%

Inmune Bio Inc invested $33.2M in research and development in fiscal year 2024. This represents an increase of 63.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

INMB Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$14K-91.0%	$155K-58.6%	$374K+106.6%	$181K+1545.5%	$11K	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$33.2M+63.6%	$20.3M+18.8%	$17.1M-16.9%	$20.5M+247.1%	$5.9M+80.3%	$3.3M
SG&A Expenses	$9.5M-1.5%	$9.6M+3.9%	$9.3M+5.3%	$8.8M+39.1%	$6.3M+5.1%	$6.0M
Operating Income	-$42.6M-43.4%	-$29.7M-14.6%	-$26.0M+11.0%	-$29.2M-138.4%	-$12.2M-57.7%	-$7.8M
Interest Expense	$357K-84.3%	$2.3M+13.1%	$2.0M+104.5%	$985K	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$42.1M-40.2%	-$30.0M-9.9%	-$27.3M+10.0%	-$30.3M-150.8%	-$12.1M-57.6%	-$7.7M
EPS (Diluted)	$-2.11-26.3%	$-1.67-9.9%	$-1.52+19.1%	$-1.88	N/A	N/A

Metric	Q3'25	Q1'25	Q3'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23
Revenue	N/A	$50K	N/A	$14K-50.0%	$28K-34.9%	$43K-6.5%	$46K+21.1%	$38K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.9M-36.0%	$7.6M-24.1%	$10.1M+15.8%	$8.7M+44.7%	$6.0M+0.4%	$6.0M+44.3%	$4.1M+0.4%	$4.1M
SG&A Expenses	$2.5M+9.9%	$2.3M+4.4%	$2.2M-5.1%	$2.3M-2.6%	$2.4M-7.2%	$2.6M+12.0%	$2.3M-0.8%	$2.3M
Operating Income	-$7.4M+25.0%	-$9.9M+19.4%	-$12.3M-11.5%	-$11.0M-31.5%	-$8.4M+1.7%	-$8.5M-33.0%	-$6.4M+0.2%	-$6.4M
Interest Expense	$250K	$0-100.0%	$145K-59.4%	$357K-23.6%	$467K-17.8%	$568K-10.0%	$631K+3.1%	$612K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$6.5M+33.5%	-$9.7M+19.5%	-$12.1M-9.7%	-$11.0M-31.1%	-$8.4M+1.8%	-$8.6M-31.7%	-$6.5M+0.5%	-$6.5M
EPS (Diluted)	$-0.24+44.2%	$-0.43+28.3%	$-0.60+1.6%	$-0.61-29.8%	$-0.47+2.1%	$-0.48-33.3%	$-0.360.0%	$-0.36

INMB Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$39.6M-30.6%	$57.0M-30.3%	$81.8M-18.2%	$99.9M+145.8%	$40.7M+66.1%	$24.5M
Current Assets	$22.7M-43.3%	$39.9M-38.2%	$64.7M-21.7%	$82.6M+244.4%	$24.0M+208.9%	$7.8M
Cash & Equivalents	$20.9M-41.6%	$35.8M-31.3%	$52.2M-30.3%	$74.8M+240.6%	$22.0M+214.0%	$7.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.2M-38.0%	$1.9M	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$7.5M-60.4%	$18.9M-13.0%	$21.7M+10.0%	$19.7M+936.8%	$1.9M+121.0%	$861K
Current Liabilities	$7.2M-60.9%	$18.5M+69.1%	$10.9M+150.5%	$4.4M+145.4%	$1.8M+153.6%	$700K
Long-Term Debt	$15.0M	N/A	$9.7M-35.4%	$15.0M	N/A	N/A
Total Equity	$32.1M-14.0%	$37.3M-37.9%	$60.1M-25.1%	$80.2M+107.0%	$38.8M+64.1%	$23.6M
Retained Earnings	-$163.1M-34.8%	-$121.0M-33.0%	-$91.0M-42.8%	-$63.7M-90.9%	-$33.4M-56.9%	-$21.3M

Metric	Q3'25	Q1'25	Q3'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23
Total Assets	$33.4M-11.8%	$37.8M-4.5%	$39.6M-15.5%	$46.8M-17.8%	$57.0M-9.1%	$62.7M-10.1%	$69.7M-5.8%	$74.0M
Current Assets	$30.7M+46.3%	$21.0M-7.5%	$22.7M-24.0%	$29.8M-25.3%	$39.9M-12.4%	$45.6M-13.3%	$52.6M-7.5%	$56.9M
Cash & Equivalents	$27.7M+43.4%	$19.3M-7.6%	$20.9M-19.5%	$26.0M-27.5%	$35.8M-14.3%	$41.8M-12.6%	$47.8M-6.2%	$51.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.7M+32.8%	$1.3M+8.6%	$1.2M	N/A	$1.9M	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.0M-1.8%	$8.1M+8.9%	$7.5M-58.1%	$17.8M-5.6%	$18.9M+5.0%	$18.0M-5.8%	$19.1M+2.0%	$18.7M
Current Liabilities	$7.4M-7.2%	$7.9M+9.8%	$7.2M-58.6%	$17.4M-5.5%	$18.5M+28.6%	$14.4M+10.0%	$13.1M+27.0%	$10.3M
Long-Term Debt	$15.0M0.0%	$15.0M0.0%	$15.0M	N/A	N/A	$12.5M-16.7%	$15.0M0.0%	$15.0M
Total Equity	$25.4M-14.5%	$29.7M-7.6%	$32.1M+13.7%	$28.2M-24.4%	$37.3M-15.0%	$43.9M-13.3%	$50.7M-8.4%	$55.3M
Retained Earnings	-$203.8M-17.9%	-$172.8M-6.0%	-$163.1M-23.5%	-$132.0M-9.1%	-$121.0M-7.5%	-$112.6M-8.2%	-$104.1M-6.7%	-$97.5M

INMB Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$33.4M-178.5%	-$12.0M+47.2%	-$22.7M+20.4%	-$28.5M-218.7%	-$8.9M-66.1%	-$5.4M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	-$15.0M	N/A	N/A
Financing Cash Flow	$18.2M+531.0%	-$4.2M-679.6%	$729K-99.2%	$96.4M+303.3%	$23.9M+95.7%	$12.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q1'25	Q3'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23
Operating Cash Flow	-$5.4M+20.3%	-$6.8M+38.0%	-$11.0M-47.3%	-$7.5M-119.8%	-$3.4M+20.2%	-$4.3M-34.3%	-$3.2M-178.2%	-$1.1M
Capital Expenditures	$193K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	-$5.6M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$193K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$0-100.0%	$5.3M+353.8%	-$2.1M+16.9%	-$2.5M0.0%	-$2.5M	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

INMB Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-304535.7%-285348.0pp	-19187.7%-12249.0pp	-6938.8%+9167.9pp	-16106.6%+95057.0pp	-111163.6%	N/A
Net Margin	-300585.7%-281225.7pp	-19360.0%-12060.8pp	-7299.2%+9463.2pp	-16762.4%+93228.5pp	-109990.9%	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-106.4%-53.7pp	-52.6%-19.3pp	-33.4%-3.0pp	-30.4%-0.6pp	-29.8%+1.6pp	-31.4%
Current Ratio	3.14+1.0	2.16-3.8	5.92-13.0	18.95+5.4	13.51+2.4	11.09
Debt-to-Equity	0.47-0.0	0.51+0.3	0.16-0.0	0.19+0.1	0.05+0.0	0.04
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q1'25	Q3'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-19810.0%	N/A	-78692.9%-48767.9pp	-29925.0%-10092.4pp	-19832.6%-5895.6pp	-13937.0%+2965.7pp	-16902.6%
Net Margin	N/A	-19478.0%	N/A	-78750.0%-48721.4pp	-30028.6%-10114.6pp	-19914.0%-5781.3pp	-14132.6%+3067.4pp	-17200.0%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-19.4%+6.4pp	-25.8%-2.8pp	-22.9%+0.6pp	-23.5%-8.8pp	-14.8%-1.1pp	-13.7%-4.3pp	-9.3%-0.5pp	-8.8%
Current Ratio	4.17+1.5	2.64-0.5	3.14+1.4	1.71-0.5	2.16-1.0	3.18-0.9	4.03-1.5	5.53
Debt-to-Equity	0.31-0.2	0.51+0.0	0.47-0.2	0.63+0.1	0.51+0.2	0.28-0.0	0.30+0.0	0.27
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Genenta Science Spa GNTA

$21.5M

Pds Biotechnology Corporation PDSB

$36.0M

Polypid Ltd. PYPD

$77.7M

JUPITER NEUROSCIENCES, INC. JUNS

$19.2M

Vtv Therapeutics VTVT

$139.1M

Frequently Asked Questions

What is Inmune Bio Inc's annual revenue?

Inmune Bio Inc (INMB) reported $14K in total revenue for fiscal year 2024. This represents a -91.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Inmune Bio Inc's revenue growing?

Inmune Bio Inc (INMB) revenue declined by 91% year-over-year, from $155K to $14K in fiscal year 2024.

Is Inmune Bio Inc profitable?

No, Inmune Bio Inc (INMB) reported a net income of -$42.1M in fiscal year 2024, with a net profit margin of -300585.7%.

What is Inmune Bio Inc's earnings per share (EPS)?

Inmune Bio Inc (INMB) reported diluted earnings per share of $-2.11 for fiscal year 2024. This represents a -26.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

How much debt does Inmune Bio Inc have?

As of fiscal year 2024, Inmune Bio Inc (INMB) had $20.9M in cash and equivalents against $15.0M in long-term debt.

What is Inmune Bio Inc's operating margin?

Inmune Bio Inc (INMB) had an operating margin of -304535.7% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Inmune Bio Inc's net profit margin?

Inmune Bio Inc (INMB) had a net profit margin of -300585.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Inmune Bio Inc's operating cash flow?

Inmune Bio Inc (INMB) generated -$33.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Inmune Bio Inc's total assets?

Inmune Bio Inc (INMB) had $39.6M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Inmune Bio Inc spend on research and development?

Inmune Bio Inc (INMB) invested $33.2M in research and development during fiscal year 2024.

How many shares does Inmune Bio Inc have outstanding?

Inmune Bio Inc (INMB) had 22M shares outstanding as of fiscal year 2024.

What is Inmune Bio Inc's current ratio?

Inmune Bio Inc (INMB) had a current ratio of 3.14 as of fiscal year 2024, which is generally considered healthy.

What is Inmune Bio Inc's debt-to-equity ratio?

Inmune Bio Inc (INMB) had a debt-to-equity ratio of 0.47 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Inmune Bio Inc's return on assets (ROA)?

Inmune Bio Inc (INMB) had a return on assets of -106.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Inmune Bio Inc's cash runway?

Based on fiscal year 2024 data, Inmune Bio Inc (INMB) had $20.9M in cash against an annual operating cash burn of $33.4M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Inmune Bio Inc's Piotroski F-Score?

Inmune Bio Inc (INMB) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Inmune Bio Inc's earnings high quality?

Inmune Bio Inc (INMB) has an earnings quality ratio of 0.79x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Inmune Bio Inc cover its interest payments?

Inmune Bio Inc (INMB) has an interest coverage ratio of -119.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Inmune Bio Inc?

Inmune Bio Inc (INMB) scores 48 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.